While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...
Setrusumab did not meet primary fracture endpoints in the ORBIT and COSMIC trials but significantly improved bone mineral density in patients with osteogenesis imperfecta. Topline data were announced ...
Trial results show setrusumab reduces the incidence of fracture and increases bone density and formation. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Zacks Investment Research on MSN
O-I Glass (OI) Reports Q1 Earnings: What Key Metrics Have to Say
O-I Glass (OI) reported $1.54 billion in revenue for the quarter ended March 2026, representing a year-over-year decline of 1.7%. EPS of $0.05 for the same period compares to $0.40 a year ago. The ...
Osteogenesis imperfecta (OI) is a genetically heterogeneous group of connective tissue disorders. Mutations in Type I collagen have been shown in a number of OI variants. Using restriction fragment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results